XEN007, A CaV2.1 Calcium Channel Modulator

XEN007 (active ingredient flunarizine) is a CNS-acting Cav2.1 and T-type calcium channel modulator that is being studied in treatment-resistant childhood absence epilepsy (CAE) and potentially other neurological disorders.

Various development strategies for XEN007 are under consideration. We have entered into key exclusive licensing agreements in order to access regulatory files and drug product manufacturing, both of which may enable advanced clinical development of XEN007.

Clinical Development

An investigator-led Phase 2 proof-of-concept study is ongoing to examine the potential clinical efficacy, safety, and tolerability of XEN007 as an adjunctive treatment in pediatric patients diagnosed with treatment-resistant childhood absence epilepsy (CAE). A presentation of promising interim data collected from a small number of patients was presented at the virtual annual meeting of the American Epilepsy Society in December 2020. Xenon continues to work with the lead investigator to include additional sites and expects that topline results from a larger data set will be available in the second half of 2021, which will inform Xenon’s decision anticipated this year regarding the future development of XEN007 in CAE.

Phase 1
Phase 2
Phase 3


for Orphan Neurological Indications